SQLite Web: event_store.db

Update row 46522 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-15T02:18:53.247056+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:41bf20a9c7d4aec7","evidence_event_ids":["evt_4cf7302955ac"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-155537.txt","as_of":"2026-04-15T02:18:53.247056+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-155537.txt","company":"Travere Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-155537.txt","article_chars":2403,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_0e313aa0a67c1dfe","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-155537.txt","content_type":"text/plain","enriched_at":"2026-04-15T05:15:25.334570+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-155537.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-155537.txt","source_event_id":"evt_4cf7302955ac","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"144","fp":"410a89e48aa63c17","kind":"sec_filing","published_at":"20260414","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-14","2026-04-13","2026-02-03","2013-02-20","2008-06-25"],"entities":[{"asset_class":"equity","name":"Travere Therapeutics, Inc.","relevance":"high","symbol":"TVTX","type":"issuer"},{"asset_class":"person","name":"Peter Heerma","relevance":"high","symbol":"","type":"reporting-owner"},{"asset_class":"broker","name":"Morgan Stanley Smith Barney","relevance":"medium","symbol":"","type":"brokerage_firm"}],"event_type":"listing","information_gaps":["The cleaned text does not explicitly state the class of securities beyond \u201cNASDAQ Common\u201d and \u201cCommon,\u201d nor does it provide the exact security ticker within the filing text excerpt.","The excerpt does not specify the total number of shares to be sold beyond the displayed 7,215 value, nor does it provide the sale price or proceeds.","The excerpt does not provide the prior known state (what was previously known vs what changed), so the \u201cdelta\u201d relative to prior filings cannot be determined from the provided text alone."],"key_facts":["SEC filing type: Form 144.","Filed as of date: 2026-04-14 (accession number 0001193125-26-155537).","Subject company: Travere Therapeutics, Inc. (CIK 0001438533; SEC file number 001-36257).","Reporting person: Peter Heerma (officer).","The Form 144 states the sale is a \u201csell to cover\u201d transaction to fund tax withholding obligations upon settlement of vested performance restricted stock units.","The filing states the sale is mandated by the issuer\u2019s election under its equity incentive plans and is not discretionary by the reporting person.","The filing includes a quantity value of 7,215 shares (as shown in the cleaned text).","The filing includes a date of performance restricted stock unit vesting/settlement reference of 04/13/2026 and a \u201cdate as of\u201d of 04/14/2026."],"numeric_claims":[{"label":"shares","value":"7,215"},{"label":"tax withholding transaction type","value":"sell to cover (mandated)"}],"primary_claim":"On 2026-04-14, Travere Therapeutics, Inc. filed SEC Form 144 for Peter Heerma\u2019s mandated \u201csell to cover\u201d sale to fund tax withholding for vested performance restricted stock units.","relevance_score":0.45,"sentiment":"neutral","source_quality":"high","summary":"Travere Therapeutics, Inc. filed a Form 144 on 2026-04-14 related to a \u201csell to cover\u201d transaction for tax withholding upon settlement of vested performance restricted stock units by reporting person Peter Heerma.","topics":["SEC Form 144","sell to cover","tax withholding","performance restricted stock units","equity incentive plans"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 144 \u00b7 Travere Therapeutics, Inc. \u00b7 Filed 20260414","ticker":"TVTX","tickers":["TVTX"],"title":"TVTX filed 144","url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-155537.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel